Cardiff Oncology to Host KOL Discussion

Cardiff Oncology, Inc. will host a Key Opinion Leader (KOL) discussion focused on first-line treatment for RAS-mutated metastatic colorectal cancer. The clinical-stage biotechnology company is leveraging PLK1 inhibition in its research and development efforts. This event aims to provide insights into the latest advancements and therapeutic strategies for this specific cancer type. Such discussions are vital for disseminating scientific knowledge and fostering collaboration within the oncology community, potentially influencing future treatment protocols.